GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Loans Receivable

HURA (TuHURA Biosciences) Loans Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Loans Receivable?

TuHURA Biosciences's Loans Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


TuHURA Biosciences Loans Receivable Historical Data

The historical data trend for TuHURA Biosciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Loans Receivable Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Loans Receivable
- - -

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial - - - - -

TuHURA Biosciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


TuHURA Biosciences Loans Receivable Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.